Jason M. Broderick

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).

Data from the phase 3 METEOR trial presented at the 2016 annual meeting of the American Society of Clinical Oncology showed that cabozantinib reduced the risk of death in patients with advanced renal cell carcinoma by 34%, compared with everolimus.

A presscast held prior to the annual meeting of the American Society of Clincal Oncology presented interim results from the phase 3 ELOQUENT-2 trial. Adding elotuzumab to lenalidomide and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed-refractory multiple myeloma.